Glyconex Incwas Founded In 2001In Alliance With The Biomembrane Institutetbifrom Washington University And Drsen Itiroh Hakomoria Member Of The National Academy Of Sciencesusa Glyconex Was The First Pharmaceutical Company In Taiwan To Combine Cancer Related Glycan Identification With Human Monoclonal Antibody Developmentglyconex Incpossesses A Complete And Detailed Technological Platform For Anti Glycan Antibody Developmentincluding Multiple Acquired Licensed Patentsour Pipeline Consists Of New Drug Development In Parallel With Biosimilarsour New Drugs Were Selected And Developed Through A Detailed Antigen Antibody Characterization And Cell Line Developmentin 2009We Licensed Gnx8 To Otsuka Pharmaceutical Co Ltd In 2019Our First In Class New Drug Gnx102 Received Fda Ind Approval In 2020We Initiated Our Clinical Trial Phase I Dose Escalation Study For Gnx102 And Received Tfda Ind Approvalin Parallelour Biosimilar Products Denosumab And Aflibercept Have Completed Different Volumes Of Pilot Studies And Data Ready For Reviewwe Aim To Look For Opportunities Of Out Licensing Our Products Or Co Develop In Cooperation
United States
